AdvaMed on Inclusion of Device Tax Repeal in Funding Agreement: “Today Is a Great Day for American Patients”

WASHINGTON, D.C. – AdvaMed President and CEO Scott Whitaker released the following statement on the announcement by congressional leadership of a funding agreement that includes full repeal of the medical device excise tax. The agreement is expected to be passed this week by Congress and signed into law by President Trump:

“Without question, today is a great day for American patients. Inclusion of full repeal of the medical device excise tax in this funding agreement means America’s medtech industry can now focus exclusively on job No. 1: innovating and bringing the medical technologies of tomorrow to patients in need.

“This truly is an overwhelmingly bipartisan win for America’s patients.

“Majority Leader McConnell and Speaker Pelosi are bringing an incredibly important opportunity to Congress this week to permanently end the threat of this innovation-killing tax. I want to thank Majority Leader McConnell, Speaker Pelosi, Democratic Leader Schumer, and Republican Leader McCarthy for their leadership and determination to do what’s best for American patients and the medtech community that serves them. This also wouldn’t have happened without the commitment and tireless efforts of the nearly 300 cosponsors of device-tax-repeal legislation in both houses. We thank President Trump and his administration for their leadership and support, and we look forward to the president signing it into law.”

# # #

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.